Mandate

Vinge has advised Main Capital and Pointsharp in connection with the acquisition of Meaplus AB and Nubibus Software AB

Vinge has advised Main Capital and its portfolio company Pointsharp in connection with Pointsharp's acquisition of Meaplus AB and Nubibus Software AB. Pointsharp is a Swedish provider of identity and access management solutions as well as secure information exchange, with operations in the Nordics, DACH and Benelux. The acquisition complements Pointsharp's existing offering with capabilities in secure digital communication and strengthens the company's position in the Swedish public-sector market, particularly in the municipal and healthcare segments. The transaction is Pointsharp's sixth add-on acquisition since Main Capital became an investment partner in November 2020.

Meaplus is a software company founded in 2015 that develops SEFOS, a digital platform for secure communication. The platform is used for the exchange of sensitive information across organisations and offers, among other things, secure messaging, file sharing, video meetings and integration into customers' systems via APIs. Meaplus has a strong position in the Swedish public sector and serves more than 180 organisations in Sweden, including municipalities, regions and healthcare providers. 

The Vinge team consisted of Filip Öhrner, Philip Moré, Alex Forsberg, Nora Karlsson and Emelie Liljeblad (M&A), Johanna Fjellström, Linn Aho and Ida Pettersson (Employment), Karl-Gustaw Tobola, Sara Eirefors and Hilda Andreasson (Banking and Finance), Ian Jonson (IP), Filippa Eriksson and Therese Baltzarsson (Corporate Commercial), Nicklas Thorgerzon (GDPR), David Olander (FDI) and Filippa Bergkvist

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026